Takeda Pharmaceutical (TAK) Interest & Investment Income (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Interest & Investment Income of $154.4 million for Q2 2026, down 69.71% year-over-year from $509.7 million in Q2 2025, and down 67.19% quarter-over-quarter from $470.6 million in Q1 2026.
Takeda Pharmaceutical (TAK) Interest & Investment Income (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Interest & Investment Income history runs 10 years deep, the most recent figure standing at $154.4 million for Q2 2026.
- In Q2 2026, Interest & Investment Income fell 69.71% year-over-year to $154.4 million; the TTM figure through Jun 2026 stood at $2.1 billion (up 50.44% YoY), while the FY2026 annual figure was $1.4 billion, up 359.08% from the prior year.
- Interest & Investment Income for Q2 2026 stood at $154.4 million, down from $470.6 million in the prior quarter.
- The five-year high for Interest & Investment Income was $1.4 billion in Q3 2025, with the low at -$165.6 million in Q1 2022.
- The 5-year median for Interest & Investment Income is $251.1 million (2024), against an average of $322.9 million.
- Peak annual rise in Interest & Investment Income reached 709.05% in 2022, while the deepest fall reached 136.92% in 2022.
- Takeda Pharmaceutical's Interest & Investment Income stood at $295.0 million in 2022, then plunged by 67.9% to $94.7 million in 2023, then increased by 29.87% to $123.0 million in 2024, then retreated by 1.21% to $121.5 million in 2025, then rose by 27.06% to $154.4 million in 2026.
- Business Quant data shows TAK's Interest & Investment Income at $154.4 million in Q2 2026, $470.6 million in Q1 2026, and $121.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 154.39 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 31.50 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 12.40 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.27 Bn | 7.61 Bn | 397.90 Mn | 5.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 154.39 Mn |
| Mar 31, 2026 | 470.59 Mn |
| Dec 31, 2025 | 121.51 Mn |
| Sep 30, 2025 | 1.40 Bn |
| Jun 30, 2025 | 509.75 Mn |
| Mar 31, 2025 | 483.73 Mn |
| Dec 31, 2024 | 123.00 Mn |
| Sep 30, 2024 | 309.06 Mn |
| Jun 30, 2024 | 197.07 Mn |
| Mar 31, 2024 | 207.16 Mn |
| Dec 31, 2023 | 94.71 Mn |
| Sep 30, 2023 | 381.54 Mn |
| Jun 30, 2023 | 193.04 Mn |
| Mar 31, 2023 | 460.40 Mn |
| Dec 31, 2022 | 295.02 Mn |
| Sep 30, 2022 | 107.03 Mn |
| Jun 30, 2022 | 471.10 Mn |
| Mar 31, 2022 | -165.63 Mn |
| Dec 31, 2021 | 36.46 Mn |
| Sep 30, 2021 | 62.35 Mn |